APX005M
APX005M is a pharmaceutical drug with 11 clinical trials. Currently 2 active trials ongoing. Historical success rate of 71.4%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
8
Early Stage
3
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
62.5%
5 of 8 finished
37.5%
3 ended early
2
trials recruiting
11
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Switch Maintenance in Pancreatic
APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma
A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)
APX005M and Doxorubicin in Advanced Sarcoma
APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
Clinical Trials (11)
Switch Maintenance in Pancreatic
APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma
A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)
APX005M and Doxorubicin in Advanced Sarcoma
APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers
CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab
Study of the CD40 Agonistic Monoclonal Antibody APX005M
APX005M in Patients With Recurrent Ovarian Cancer
Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma
All 11 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 11